Want to see IN:GUJTHEM full AI Analyst Report?
Top Page
Gujarat Themis Biosyn Ltd
(GUJTHEM)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹380.00
â–¼(-12.04% Downside)
Action:Reiterated
Date:10/24/26
The score is held back primarily by weak cash-flow quality (lower operating cash flow and significantly negative free cash flow) and higher leverage despite strong reported profitability and rapid revenue growth. Technicals add downside pressure with the stock trading below major moving averages and negative MACD. Valuation is also a headwind due to the high P/E and low dividend yield.
Positive Factors
Rapid Revenue Growth
Revenue growth of roughly 107% materially expands the company’s operating scale and potential earnings base. If demand remains durable across its pharmaceutical products and markets, the larger revenue platform can support reinvestment, broader customer reach, and stronger competitive relevance.
Negative Factors
Sharp Gross-Margin Compression
The steep gross-margin decline shows that rapid revenue expansion has not translated proportionally into gross profit. If the lower margin reflects a lasting product mix or cost change, it could constrain earnings conversion and weaken the durability of reported profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Revenue growth of roughly 107% materially expands the company’s operating scale and potential earnings base. If demand remains durable across its pharmaceutical products and markets, the larger revenue platform can support reinvestment, broader customer reach, and stronger competitive relevance.
Read all positive factors
Gujarat Themis Biosyn Ltd (GUJTHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹48.79B
Dividend Yield0.18%
Average Volume (3M)18.71K
Price to Earnings (P/E)84.1
Beta (1Y)1.95
Revenue Growth17.51%
EPS Growth9.17%
CountryIN
Employees221
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.41
Shares Outstanding130,151,700
10 Day Avg. Volume17,497
30 Day Avg. Volume18,713
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Gujarat Themis Biosyn Ltd Business Overview & Revenue Model
Company Description
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds s...
Gujarat Themis Biosyn Ltd Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
64
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 800.74M | 1.66B | 1.51B |
| Gross Profit | 642.88M | 769.25M | 1.19B |
| EBITDA | 390.15M | 779.58M | 714.23M |
| Net Income | 262.62M | 466.81M | 487.72M |
Balance Sheet | |||
| Total Assets | 3.77B | 5.03B | 3.01B |
| Cash, Cash Equivalents and Short-Term Investments | 103.83M | 64.18M | 116.94M |
| Total Debt | 714.92M | 1.62B | 304.70M |
| Total Liabilities | 1.12B | 2.16B | 529.31M |
| Stockholders Equity | 2.64B | 2.88B | 2.48B |
Cash Flow | |||
| Free Cash Flow | -600.86M | -1.28B | -251.22M |
| Operating Cash Flow | 710.39M | 447.42M | 910.29M |
| Investing Cash Flow | -1.30B | -1.73B | -1.12B |
| Financing Cash Flow | 567.21M | 1.21B | 260.14M |
Gujarat Themis Biosyn Ltd Technical Analysis
Positive
432.00
Price Trends
393.73
Negative
383.11
Negative
357.54
Positive
Market Momentum
-11.55
Negative
50.70
Neutral
67.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUJTHEM, the sentiment is Positive. The current price of 432 is above the 20-day moving average (MA) of 366.80, above the 50-day MA of 393.73, and above the 200-day MA of 357.54, indicating a neutral trend. The MACD of -11.55 indicates Negative momentum. The RSI at 50.70 is Neutral, neither overbought nor oversold. The STOCH value of 67.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GUJTHEM.
Gujarat Themis Biosyn Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹54.26B | 32.33 | ― | 0.54% | 18.56% | 60.06% | |
61 Neutral | ₹65.56B | 46.61 | ― | 0.17% | 30.20% | 91.17% | |
58 Neutral | ₹42.16B | 57.21 | ― | 0.02% | 16.70% | 18.73% | |
57 Neutral | ₹53.41B | 522.46 | ― | 16.67% | 10.83% | -89.83% | |
56 Neutral | ₹35.50B | 11.66 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹48.79B | 84.07 | ― | 0.18% | 17.51% | 9.17% |
* General Sector Average
IN:GUJTHEM
Gujarat Themis Biosyn Ltd
362.50
-99.80
-21.59%
IN:GUFICBIO
Gufic Biosciences Limited
412.20
87.48
26.94%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
177.75
86.39
94.56%
IN:MOREPENLAB
Morepen Laboratories Limited
113.70
66.17
139.21%
IN:ORCHPHARMA
Orchid Pharma Limited
833.05
107.15
14.76%
IN:UNICHEMLAB
Unichem Laboratories Limited
483.45
13.70
2.92%
Gujarat Themis Biosyn Ltd Corporate Events
Gujarat Themis Biosyn files scrutinizer’s report and voting results for 45th AGM
Oct 1, 2026
Gujarat Themis Biosyn Ltd has reported the scrutinizer’s findings and detailed voting results for the resolutions placed before shareholders at its 45th Annual General Meeting held on 30 September 2026. The company submitted these outcomes, ...
Gujarat Themis Biosyn Revises Filing on 45th AGM, Confirms Dividend and Director Reappointment
Sep 30, 2026
Gujarat Themis Biosyn Ltd has issued a revised outcome of its 45th Annual General Meeting after correcting a typographical error in an earlier submission to the BSE and NSE. The AGM was held on September 30, 2026 at the company’s Vapi facili...
Gujarat Themis Biosyn Sets 45th AGM to Approve Accounts, Dividend and Board Commission
Sep 4, 2026
Gujarat Themis Biosyn Ltd, a pharmaceutical manufacturer specializing in fermentation-based intermediates and APIs, operates out of Vapi, Gujarat, with a supporting office in Mumbai. Its business model centers on regulated pharma production, and i...
Gujarat Themis Biosyn Raises Rs 750 Crore via QIP, Expands Equity Base
Aug 28, 2026
Gujarat Themis Biosyn Ltd has completed a qualified institutions placement of 21,186,440 equity shares with qualified institutional buyers at an issue price of Rs 354 per share, raising approximately Rs 750 crore. The issue price reflects a discou...
Gujarat Themis Biosyn Closes QIP, Prices Rs. 354 Equity Issue
Aug 28, 2026
Gujarat Themis Biosyn has closed its qualified institutions placement of equity shares with the fund-raising committee approving the end of the issue period after receiving applications and funds from eligible institutional buyers. The company has...
Gujarat Themis Biosyn Board Clears QIP Issue at ₹372.57 Floor Price
Aug 25, 2026
Gujarat Themis Biosyn Ltd has approved the launch of a qualified institutions placement of equity shares with a face value of ₹1 to raise capital from qualified institutional buyers. The board adopted the preliminary placement document, auth...
Gujarat Themis Biosyn Files Audited FY26 Results With Clean Audit Opinion
Aug 25, 2026
Gujarat Themis Biosyn Ltd has released its audited financial statements for the quarter and full year ended March 31, 2026, following board approval in May. The disclosure has been made to both BSE and NSE in line with SEBI’s listing require...
Gujarat Themis Biosyn Amends Articles to Loosen Share Issuance Valuation Rules
Aug 23, 2026
Gujarat Themis Biosyn Ltd has secured shareholder approval via a special resolution at an Extraordinary General Meeting on 22 August 2026 to amend its Articles of Association. The amendment, disclosed under SEBI Listing Obligations and Disclosure ...
Gujarat Themis Biosyn Shareholders Approve Key Amendment to Articles of Association
Aug 23, 2026
Gujarat Themis Biosyn Ltd has amended its Articles of Association following shareholder approval via a special resolution passed through a postal ballot on 22 August 2026. The change targets Article 13(1), Clause (c), which governs the companyR...
Gujarat Themis Biosyn Secures Shareholder Nod for QIP Fundraising Plan
Aug 22, 2026
Gujarat Themis Biosyn Ltd has reported the results of a postal ballot conducted via remote e-voting to approve a special resolution for raising funds through an issue of equity shares via Qualified Institutions Placement. The promoter group did no...
Gujarat Themis Biosyn Publishes Q1 FY27 Earnings Call Transcript
Aug 14, 2026
Gujarat Themis Biosyn Limited has released the transcript of its Q1 FY27 earnings conference call with analysts and investors, held on August 10, 2026. The call, led by Managing Director Dr. Sachin Patel and Chief Financial Officer Krupesh Patel, ...
Gujarat Themis Biosyn Publishes Q1 FY27 Unaudited Results in Line with SEBI Norms
Aug 8, 2026
Gujarat Themis Biosyn Ltd is an India-based pharmaceutical and biosciences company, operating a manufacturing facility in Vapi, Gujarat and maintaining a corporate office in Mumbai. It is listed on BSE and NSE, reflecting a long-standing presence ...
Gujarat Themis Biosyn Sets August EGM, Activates Remote E-Voting
Aug 1, 2026
Gujarat Themis Biosyn Ltd has notified the stock exchanges that it has published a newspaper advertisement regarding an upcoming Extra-Ordinary General Meeting. The company has circulated the EGM notice electronically to shareholders with register...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.